Cornea | Ophthalmology Innovation Source

LacriPen Writing Exciting Script for Founders

Interview

Ocular Therapeutix Taking Aim at Allergy Market

Amar Sawhney, PhD, Chairman, Chairman, President & CEO of Ocular Therapeutics, touts the performance of Dextenza, the company’s anti-allergy medication. Instead of taking one drop a day, allergy sufferers just need one treatmet of Dextenza to survive a whole season. Speaking With: Amar Sawhney, PhD Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006, has since…

`Mythbuster’ Cheskin on Powervision’s Future Pipeline, Strength of IOLs

Barry Cheskin, co-founder, president, and CEO of PowerVision, introduces the company’s next iteration, Fluidvision 2020, a new IOL that doubles the power of accommodation for patients. PowerVision expects to have the IOL in clinics next year. Citing the lens’ clinical data, he also busts a myth about IOLs’ lifetime in the lens capsule. Speaking With:…

Orca Aggressively Pursues Cataract Surgery Market

Yariv Bar-On, CEO of Orca Surgical, explains how his company is trying to change how surgeons remove the corneal epithelium during ophthalmic laser surgery. Orca says its flagship Epi Clear dynamic epikeratome device will introduce a “new paradigm for laser-assisted refractive surgery that is safer and less painful than existing microkeratome flap keratomileusis and advanced…

Tarantino on How AcuFocus Found Success Rolling Out KAMRA

Acufocus’ Nick Tarantino, Chief Global Clinical Research & Regulatory Affairs Officer, explains how AcuFocus is taking a “nice and measured” approach to rolling out its KAMRA inlay as a treatment for presbyopia. The KAMRA inlay received US approval on April 17, 2015, making it the first corneal inlay to achieve this landmark. Since approval, the…

Oculeve’s Ackermann Talks Allergan

Michael Ackermann, CEO of start-up Oculeve, gives an update on his work with Allergan following the purchase of his company and its Dry Eye device. Ackermann explains how he’s fitting into Allergan’s folds and when we might expect to see Oculeve’s neurostimulation device. Speaking With: Michael Ackermann, PhD Michael is currently Vice President, Neurostimulation for…

LacriScience

LacriScience is in late stage development of its LacriPen, a portable instrument using gold plated single-use sensors that measures osmolarity to +/- 2 mOSM/L and proteins. By coating the gold film with a specific antibody, such as Adenovirus, Herpes Zoster, Herpes Simplex, or any biomaker, it can be precisely identified or quantified instantly. www.lacripen.com Participant:…

ReVision Optics

The presbyopia market is estimated to comprise more than 2 billion people by 2020. ReVision Optics has developed the Raindrop Near Vision inlay to address that market, with a potential of 30 million eligible patients. The Raindrop itself is a 2-mm diameter hydrogel inlay, 30 microns thick. It’s 80% water. It’s clear, so it enables…

Avedro

Avedro has submitted its New Drug Application for its riboflavin ophthalmic solution/KXL System (corneal cross-linking for the treatment of keratoconus and corneal ectasia following refractive surgery), and has a PDUFA date of April 16. In February 2015, the company presented to the FDA Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Devices Panel of the…

RPS Diagnostics

RPS is a diagnostic company concentrating on inflammatory and infectious disease diagnoses; its flagship product, the InflammaDry, has been designed for in-office diagnosis of inflammatory conditions present in a patient’s eye. The company has devised two platforms: one, an amino-based platform using antibodies to detect disorders. The second, novel platform is a molecular test that…

Ora’s Ousler Delves Deep Into Dry Eye

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 064″] Dry Eye remains one of the more dynamic sectors of ophthalmology with Shire’s recent news about its lead Lifitegrast product moving toward FDA approval. Ora knows Dry Eye better than most, and Vice President George Ousler helps fill in the blanks about Dry Eye’s future. Ora also published a paper…

Muller On The FDA, PIXL And Dairy Farms

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 063″] Avedro CEO David Muller updates us on Avedro’s securing FDA approval for its KXL System. He also tells us what he learned on his dairy farm in Vermont. Podcast Description for Web: Avedro’s long saga with the FDA continues. Last week, the firm resubmitted the NDA for its riboflavin ophthalmic…